Neptune PVT-2201-201 (Non-Infectious Uveitis) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the use of an investigational drug called brepocitinib (the study drug) for active, non-infectious uveitis (NIU). We want to know if the study drug is a safe and effective option to decrease the inflammation associated with NIU.

What is the Condition Being Studied?

Non-Infectious Uveitis (Intermediate, Posterior, or Panuveitis)

Who Can Participate in the Study?

Adults ages 18-75 who:
- Are diagnosed with non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis);
- Are not currently taking a systemic corticosteroid

For more information about who can be in this study, please contact the study team at

Age Group

What is Involved?

If you choose to join the study, you will:
- Take the study drug in addition to any other medications you are already taking, and the dose of the study drug will be randomly decided (by chance, like flipping a coin)
- Be in touch with the study team for about 14 months
- Visit our clinic at the Duke Eye Center every 3 to 6 weeks for the first 6 months of the study, and then every 2 to 3 months until the end of the study

At various visits, you will have blood draws, answer questionnaires, and have eye exams and vision tests.

Study Details

Full Title
A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Pan-uveitis
Principal Investigator
Protocol Number
IRB: PRO00111864
NCT: NCT05523765
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center